Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ).
ImmuneOnco Biopharmaceuticals has announced that its partner, Instil Bio, has received IND clearance from the U.S. FDA for IMM2510/AXN-2510, a bispecific antibody for solid tumors. This development paves the way for a Phase 1b/2 trial in the U.S. by the end of 2025, potentially enhancing the company’s market position in cancer therapies.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative therapies for cancer treatment. The company is involved in the development of a PD-L1 and VEGF bispecific antibody, IMM2510/AXN-2510, aimed at treating multiple solid tumor cancers.
Average Trading Volume: 4,990,321
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.34B
For detailed information about 1541 stock, go to TipRanks’ Stock Analysis page.